WO2025003513 - OTOFERLIN GENE TRANSFER
National phase entry is expected:
Publication Number
WO/2025/003513
Publication Date
02.01.2025
International Application No.
PCT/EP2024/068451
International Filing Date
01.07.2024
Title **
[English]
OTOFERLIN GENE TRANSFER
[French]
TRANSFERT DE GÈNE D'OTOFERLINE
Applicants **
KATHOLIEKE UNIVERSITEIT LEUVEN
KU Leuven Research & Development Waaistraat 6 - Box 5105
3000 Leuven, BE
Inventors
DE VIN, Filip
c/o KULeuven R&D
Waaistraat 6 - box 5105
3000 Leuven, BE
HENCKAERTS, Els
c/o KULeuven R&D
Waaistraat 6 - box 5105
3000 Leuven, BE
Priority Data
23182462.4
29.06.2023
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1021 | |
| EPO | Filing, Examination | 4736 | |
| Japan | Filing | 587 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 2710 |
Total: 9628 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The invention relates to a first fusion protein comprising N-terminally an N-terminal fragment of otoferlin and C-terminally an N-terminal fragment of an intein, and a second fusion protein comprising N-terminally a C-terminal fragment of an intein and C-terminally a C-terminal fragment of intein.[French]
L'invention concerne une première protéine de fusion comprenant N-terminalement un fragment N-terminal d'otoferline et C-terminalement un fragment N-terminal d'une intéine, et une seconde protéine de fusion comprenant N-terminalement un fragment C-terminal d'une intéine et C-terminalement un fragment C-terminal d'intéine.